Clinical Efficacy of Magnesium Sulfate Injection in the Treatment of Masseter Muscle Trigger Points: a Randomized Clinical Study

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2022 Sep 19

PMID 36123724

Authors

Shaimaa Mohsen Refahee

Aliaa Ibrahim Mahrous

Alshaimaa Ahmed Shabaan

Affiliations

Soon will be listed here.

Abstract

Objective: Myofascial pain syndrome with trigger points is the most common cause of nonodontogenic pain. Although injection of the trigger points is the most effective pain reduction treatment, many patients exhibit recurrence after a short period. Therefore, the aim of the current study was to evaluate the clinical efficacy of magnesium sulfate injections in the treatment of the masseter muscle trigger points when compared to saline injections.

Material And Method: This study randomly (1:1) assigned 180 patients to one of two treatment groups based on whether their trigger points were injected with 2 ml of saline or magnesium sulfate. Pain scores, maximum mouth opening (MMO), and quality of life were measured at the pre-injection and 1, 3, and 6 months post-injection.

Results: The pain scores were significantly higher in the saline group during all follow-up assessments, whereas the MMO was significantly higher in the magnesium sulfate group up to 3 months of follow-up (p < 0.001). However, the difference in MMO ceased to be statistically significant after 6 months of follow-up (p = 0.121). Additionally, the patient's quality of life score was significantly higher in the magnesium sulfate group compared to the saline group (p < 0.001).

Conclusion: Injection of magnesium sulfate is an effective treatment measure for myofascial trigger points. However, further studies with a proper design addressing the limitations of the current study are necessary.

Clinicaltrials: org (ID: NCT04742140) 5/2/2021.

Citing Articles

Effectiveness of intra-oral botulinum toxin injection in comparison to the extra-oral approach on pain and quality of life in patients with myofascial pain: a randomized clinical trial.

Shabaan A, Kassem I, Aboulmagd I, Amer I, Shaaban A, Abd-El-Ghafour M Clin Oral Investig. 2024; 29(1):18.

PMID: 39681752 PMC: 11649703. DOI: 10.1007/s00784-024-06051-0.

Role of Magnesium in Skeletal Muscle Health and Neuromuscular Diseases: A Scoping Review.

Liguori S, Moretti A, Paoletta M, Gimigliano F, Iolascon G Int J Mol Sci. 2024; 25(20).

PMID: 39457008 PMC: 11508242. DOI: 10.3390/ijms252011220.

Efficacy of different low-level laser therapy sessions in the management of masseter muscle trigger points.

Mahmoud N, Shehab W, AlAraby A, Habaka Y BMC Oral Health. 2024; 24(1):1125.

PMID: 39327563 PMC: 11428541. DOI: 10.1186/s12903-024-04780-y.

Nutritional Strategies for Chronic Craniofacial Pain and Temporomandibular Disorders: Current Clinical and Preclinical Insights.

Piriyaprasath K, Kakihara Y, Hasegawa M, Iwamoto Y, Hasegawa Y, Fujii N Nutrients. 2024; 16(17).

PMID: 39275184 PMC: 11397166. DOI: 10.3390/nu16172868.

Magnesium Sulfate and Its Versatility in Anesthesia: A Comprehensive Review.

Dahake J, Verma N, Bawiskar D Cureus. 2024; 16(3):e56348.

PMID: 38633961 PMC: 11021848. DOI: 10.7759/cureus.56348.

References

Wang H, Liang Q, Cheng L, Li X, Fu W, Dai W . Magnesium sulfate enhances non-depolarizing muscle relaxant vecuronium action at adult muscle-type nicotinic acetylcholine receptor in vitro. Acta Pharmacol Sin. 2011; 32(12):1454-9. PMC: 4010211. DOI: 10.1038/aps.2011.117. View

Fiorillo L . Spine and TMJ: A Pathophysiology Report. J Funct Morphol Kinesiol. 2021; 5(2). PMC: 7739216. DOI: 10.3390/jfmk5020024. View

Yilmaz O, Sivrikaya E, Taskesen F, Pirpir C, Ciftci S . Comparison of the Efficacy of Botulinum Toxin, Local Anesthesia, and Platelet-Rich Plasma Injections in Patients With Myofascial Trigger Points in the Masseter Muscle. J Oral Maxillofac Surg. 2020; 79(1):88.e1-88.e9. DOI: 10.1016/j.joms.2020.09.013. View

Nitecka-Buchta A, Walczynska-Dragon K, Kempa W, Baron S . Platelet-Rich Plasma Intramuscular Injections - Antinociceptive Therapy in Myofascial Pain Within Masseter Muscles in Temporomandibular Disorders Patients: A Pilot Study. Front Neurol. 2019; 10:250. PMC: 6433706. DOI: 10.3389/fneur.2019.00250. View

Wong C, Wong S . A new look at trigger point injections. Anesthesiol Res Pract. 2011; 2012:492452. PMC: 3182370. DOI: 10.1155/2012/492452. View

LeResche L . Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med. 1997; 8(3):291-305. DOI: 10.1177/10454411970080030401. View

Slade G, Spencer A . Development and evaluation of the Oral Health Impact Profile. Community Dent Health. 1994; 11(1):3-11. View

Sakalys D, Rokicki J, Januzis G, Kubilius R . Plasma rich in growth factors injection effectiveness for myofascial pain treatment in masticatory muscles. Randomised controlled trial. J Oral Rehabil. 2020; 47(7):796-801. DOI: 10.1111/joor.12973. View

Celiker R, Atalay A, Guven Z . Health-related quality of life in patients with myofascial pain syndrome. Curr Pain Headache Rep. 2010; 14(5):361-6. DOI: 10.1007/s11916-010-0141-7. View

10.

Bian Z, Shang H . CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2011; 154(4):290-1. DOI: 10.7326/0003-4819-154-4-201102150-00016. View

11.

Frost H . A 2003 update of bone physiology and Wolff's Law for clinicians. Angle Orthod. 2004; 74(1):3-15. DOI: 10.1043/0003-3219(2004)074<0003:AUOBPA>2.0.CO;2. View

12.

Gerwin R . Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep. 2001; 5(5):412-20. DOI: 10.1007/s11916-001-0052-8. View

13.

Bakke M, Moller E . Craniomandibular disorders and masticatory muscle function. Scand J Dent Res. 1992; 100(1):32-8. DOI: 10.1111/j.1600-0722.1992.tb01806.x. View

14.

Reiter S, Goldsmith C, Emodi-Perlman A, Friedman-Rubin P, Winocur E . Masticatory muscle disorders diagnostic criteria: the American Academy of Orofacial Pain versus the research diagnostic criteria/temporomandibular disorders (RDC/TMD). J Oral Rehabil. 2012; 39(12):941-7. DOI: 10.1111/j.1365-2842.2012.02337.x. View

15.

Ng K, Yap J, Izham I, Teoh W, Kwok P, Koh W . The effect of intravenous magnesium on postoperative morphine consumption in noncardiac surgery: A systematic review and meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2020; 37(3):212-223. DOI: 10.1097/EJA.0000000000001164. View

16.

Okeson J, de Leeuw R . Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2010; 55(1):105-20. DOI: 10.1016/j.cden.2010.08.007. View

17.

Romero-Reyes M, Uyanik J . Orofacial pain management: current perspectives. J Pain Res. 2014; 7:99-115. PMC: 3937250. DOI: 10.2147/JPR.S37593. View

18.

Fernandez-Carnero J, La Touche R, Ortega-Santiago R, Galan-Del-Rio F, Pesquera J, Ge H . Short-term effects of dry needling of active myofascial trigger points in the masseter muscle in patients with temporomandibular disorders. J Orofac Pain. 2010; 24(1):106-12. View

19.

Alvarez D, Rockwell P . Trigger points: diagnosis and management. Am Fam Physician. 2002; 65(4):653-60. View

20.

Ahmed S, Magdy A, Abdullah M, Albadry A . The Effect of Erector Spinae Plane Block With and Without Addition of Magnesium on Relief of Pain from Post-herpetic Neuralgia. Pain Physician. 2022; 25(5):365-372. View